ArticleBMC pulmonary medicine2025
Evaluating the impact of altitudinal variations on COVID-19 mortality rates: a comprehensive analysis.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Variation of the Neutrophil-to-Lymphocyte Ratio and Mean Platelet Volume in a Multicenter Study of Critically Ill Patients with COVID-19 Living at Different Altitudes.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh altitude, known for its effects on respiratory diseases, was analyzed for its potential protective role. Data from the New York Times COVID-19 repository, U.S. Census Bureau, and topographic maps were utilized, covering January 2020 to August 2022, including pre- and post-vaccination periods. This study investigates the influence of high altitude on COVID-19 mortality, fatality rates, and vaccination outcomes in the United States. COVID-19, caused by SARS-CoV-2, has shown significant disparities in severity and outcomes across populations.
methodsThis study utilized publicly available data from the New York Times COVID-19 repository and the US Census Bureau's American Community Survey to analyze case fatality rates across mainland US counties from January 21, 2020, to August 13, 2022. Average altitude data were obtained from topographic maps, and counties outside the mainland USA were excluded. Vaccination-related data were assessed using the cutoff date of December 14, 2020. The rural-urban status of counties was determined using the Index of Relative Rurality (IRR) from Waldorf and Kim's study, which included 3105 of 3109 counties.
resultsCounties above 1500 m exhibited significantly lower case numbers, deaths, cases per million, and fatality rates compared to counties below this altitude. Pre-vaccination fatality rates were notably reduced in high-altitude regions (p = 0.0001), while post-vaccination data continued to demonstrate lower fatality rates (p < 0.0001). A positive correlation between rurality and post-vaccination fatality rates was observed (rho = 0.176, p = 0.0001). Altitude, alongside vaccination status, was identified as a critical factor influencing fatality rates (p = 0.001 for both). Additionally, a significant positive correlation between rurality (Index of Relative Rurality) and post-vaccination fatality rates was observed (rho = 0.176, p = 0.0001).
conclusionsOur findings highlight that high-altitude adaptations, such as increased lung capacity and epigenetic changes, may mitigate COVID-19 severity. However, the role of environmental and genetic factors remains insufficiently explored. Importantly, the study underscores healthcare inequities in rural high-altitude areas, where limited vaccination access exacerbates mortality risks. While altitude shows promise as a protective factor, addressing healthcare access disparities and further investigating high-altitude physiological and genetic adaptations are imperative for optimizing COVID-19 outcomes in diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.